AMETEK(AME) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - AMETEK reported record sales of $2 billion in Q4 2025, a 13% increase from Q4 2024, with organic sales up 5% and acquisitions contributing 7% [6][5] - Operating income reached a record $523 million, a 12% increase year-over-year, with operating margins at 26.2% [7][5] - Diluted earnings per share were a record $2.01, up 7% from the previous year, exceeding guidance [8][5] - Free cash flow was a record $527 million, up 6% year-over-year, with a conversion rate of 132% [8][24] Business Line Data and Key Metrics Changes - The Electronic Instruments Group (EIG) achieved sales of $1.37 billion, up 13% from the previous year, with organic sales growth of 2% [9] - The Electromechanical Group (EMG) reported sales of $629 million, a 15% increase, with organic sales up 14% [10] - Both groups demonstrated strong operating performance, with EIG's operating income at $413.7 million and EMG's at $142.5 million, reflecting increases of 7% and 28% respectively [9][10] Market Data and Key Metrics Changes - Overall orders increased by 18% to a record $2 billion, with organic orders up 7% [7] - Sales growth was strong across all geographic regions, with the U.S. and Asia both showing mid-single-digit growth, while Europe experienced low single-digit growth [44] Company Strategy and Development Direction - AMETEK announced the acquisition of LKC Technologies, enhancing its med tech exposure and broadening its ophthalmic portfolio [12][13] - The company plans to continue its acquisition strategy, with a focus on high-quality candidates and maintaining an investment-grade credit rating while deploying over $5 billion in capital [14] - Investments in research, development, and technology innovation are expected to increase, with an incremental $100 million planned for 2026 [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate economic uncertainties and maintain strong growth, with expectations for mid- to high-single-digit sales growth in 2026 [18][19] - The company anticipates organic sales growth of low- to mid-single digits, with diluted earnings per share expected to rise 6%-9% [18] Other Important Information - AMETEK's general and administrative expenses increased slightly, with expectations for them to remain around 1.5% of sales in 2026 [21][22] - The effective tax rate for 2026 is anticipated to be between 18.5% and 19.5% [22] Q&A Session Summary Question: Can you provide insights into the medical portfolio performance? - The broader healthcare exposure accounts for 21% of the business, with Paragon and Rauland showing low double-digit growth in Q4 and high single digits for the full year [28] Question: What is the outlook for strategic price capture? - The company expects to offset inflation and tariffs in 2026, maintaining a positive price-cost spread [30] Question: Can you discuss the end markets and regional dynamics? - Process businesses saw mid-teens growth in Q4, while aerospace and defense businesses experienced low double-digit growth [38][40] Question: What is the status of the FARO acquisition? - The integration is progressing well, with expectations to double EBITDA margins from mid-teens to 30% within three years [71] Question: How is the M&A pipeline looking for 2026? - The pipeline is strong, with a mix of normal quality and larger deals, and the company is actively looking for high-quality acquisitions [96][100]